Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9ULM6
UPID:
CNOT6_HUMAN
Alternative names:
CCR4 carbon catabolite repression 4-like; Carbon catabolite repressor protein 4 homolog; Cytoplasmic deadenylase
Alternative UPACC:
Q9ULM6; A7MD46; D3DWR0
Background:
CCR4-NOT transcription complex subunit 6, known as CCR4 carbon catabolite repression 4-like, plays a pivotal role in mRNA degradation, miRNA-mediated repression, and translational repression. It is a key component of the CCR4-NOT complex, influencing mRNA expression and cellular processes such as cell proliferation and survival. Its involvement in the mRNA decay of the FOS gene and enhancement of nuclear hormone receptors' transcriptional activity underscores its multifunctionality.
Therapeutic significance:
Understanding the role of CCR4-NOT transcription complex subunit 6 could open doors to potential therapeutic strategies.